CMB International Global Markets | Equity Research | Market Strategy



China / HK Market Weekly

HK market's rerating continues

Last week (13-17 Jun), US S&P 500 Index declined by over 5% for the second consecutive week, as the Fed raised interest rates by 75 bps bringing inflation down. China / HK stock markets outperformed. Looking ahead to this week, market focus will still be on central banks. The PBOC will announce LPR on Monday, and Fed Chair Powell will give a semi-annual testimony before the Congress on Wednesday & Thursday. China Internet, Healthcare & Consumer Discretionary stocks may remain volatile this week as investors digest Fed's tightening, but we continue to see medium-term re-rating potential. Among Value stocks, Financials are more defensive than Commodities.

- Market recap: The HSI / CSI 300 returned -3.4% / 1.7% last week, extending their strong runs relative to developed markets over the past few weeks. In HK, all major sectors declined, while in A-shares market, Healthcare & Consumer Discretionary led gains. China Growth stocks are on the verge of bucking an 18-month downtrend relative to Value stocks (Fig. 7).
- Fund flows: Global equity funds flew out of EM as higher-than-expected inflation in the US spiked faster tightening of the Fed. But equity fund flows to China continued to improve as the country was in the liquidity easing and economic resumption cycle. US equity funds continued to see withdrawals.
- Stock Connect flows: Weekly Northbound net inflows stayed high, and Southbound net inflows increased WoW (Fig. 16-17). By sector, Southbound funds flew into Consumer Discretionary, IT, Energy, Industrials and Healthcare, and out of Conglomerates and Financials. Northbound funds flew into Food, Beverage & Tobacco, Banking, Hardware & Equipment, Semiconductors and Software & Services, and out of Materials and Utilities.
- Interest rates: UST yield curve flattened as short yields jumped more on Fed rate hike bets. Implied Fed funds rate in Dec 2022 rose to 3.57%. HK dollar liquidity gradually tightened as USD/HKD reached the weak-side 7.85.
- Sentiments: Risk appetite mildly decreased in HK due to US rate hike. "Fear Index" VHSI rose to 31.1. Short-sell ratio on HK mainboard rebounded from 3-month low to 17.1%.
- Earnings: FY22E EPS consensus of the HSI / HSTECH / CSI 300 were revised down by 1.0% / 2.6% / 0.8% last week (Fig. 43-45). In HK, IT, Healthcare & Consumer Discretionary got earnings. In A-shares, Financials & Staples got upward revision, while IT & Healthcare was revised down.
- Valuation gaps between HK and other major markets have narrowed, as HSI's forward P/E is approaching 10-yr mean after earnings cuts and re-rating, while those of the US / Europe / Japan dropped to below 10-yr mean after recent weakness (Fig. 39).
- Sector views: China Growth stocks such as Internet, Healthcare & Consumer Discretionary may remain volatile this week as investors digest Fed's tightening, but we continue to see re-rating potential over the medium term. Among Value stocks, Financials are more defensive, but Commodities may underperform as investors become more concerned on global economic slowdown and higher interest rates.


Daniel So, CFA (852) 3900 0857 danielso@cmbi.com.hk

Bingnan YE, Ph.D (852) 3761 8967 yebingnan@cmbi.com.hk

	ASIAMONEY
Please	cast your valuable vote for CMBIS research team in the 2022 Asiamoney Brokers Poll
	VOTE




Market Recap





Source: Bloomberg, CMBIGM

Figure 3: Hang Seng Composite Index sectors: down across the board




Source: Bloomberg, CMBIGM






Source: Bloomberg, CMBIGM

Figure 2: HSI fell on Fed rate hike, and ranged bound between 20700-21500



Source: Bloomberg, CMBIGM

Figure 4: CSI 300 Index sectors: Healthcare & **Consumer led gains**



Source: Bloomberg, CMBIGM




Source: Bloomberg, CMBIGM


Figure 6: IT, Healthcare & Consumer Discretionary moved to "Leading" zone in daily Relative Rotation Graph, indicating strong short-term momentum



Figure 7: China Growth stocks outperformed Value in recent weeks, on the verge of breaking a downtrend on the chart of relative performance



Fund Flows



Source: IIF, CMBIGM







Figure 10: USD & HKD Interest Rates











Figure 11: USD/HKD Rates & Interest Spreads










Figure 14: US-China 10-year yield spread widened further as China's yield stayed flat




Source: Bloomberg, CMBIGM


SH/SZ-HK Stock Connect


















Source: Bloomberg, CMBIGM














Figure 19: Northbound flows increased recently









Figure 22: Southbound net flows by sector last week





Source: Bloomberg, CMBIGM



Figure 24: Southbound weekly Top 10 active stocks

(HKD mn, cumulative)		Turnover	Net Buying
Tencent	700 HK	13,060	996
Meituan	3690 HK	13,933	1,706
CNOOC	883 HK	7,133	2,053
Kuaishou	1024 HK	6,596	833
GCL Technology	3800 HK	2,473	963
China Construction Bank	939 HK	377	-246
Sunny Optical	2382 HK	648	-240
Geely Automobile	175 HK	270	185
China Shenhua Energy	1088 HK	1,052	-84
Xiaomi	1810 HK	1,293	323

(RMB mn, cumulative) Turnover Net Buying **Kweichow Moutai** 600519 CH 8,026 -456 Inner Mongolia Yili 600887 CH 4,544 2,260 LONGi Green Energy 601012 CH 7 5,230 China Merchants Bank 600036 CH 4,669 521 Ping An Insurance Group 601318 CH 4,331 -282 Industrial Bank 601166 CH 2,408 -309 TBEA 600089 CH 4,117 1,404 **CITIC Securities** 2,306 600030 CH -101 600438 CH 3,206 Tongwei 597 Shaanxi Coal Industry 601225 CH 660 323


Figure 25: Northbound (SH) Top 10 active stocks

Source: Wind, CMBIGM

Source: Wind, CMBIGM

Sentiments

Figure 26: "Fear Indexes" VHSI & VIX rose to 31.1 as a hawkish Fed caused volatility



Source: Bloomberg, CMBIGM

Figure 28: Short sell % in HK - Financials




Source: Bloomberg, CMBIGM

Figure 27: Short sell % on HK mainboard rebounded to above 17%



Source: Bloomberg, CMBIGM


Figure 29: Short sell % in HK – Info Tech



Source: Bloomberg, CMBIGM

















Source: Bloomberg, CMBIGM

8/2021



30000

28000

26000


24000

22000

20000

18000

6/2021



10/2021 12/2021

HSCI - Consumer Staples (LHS)


2/2022

4/2022



Short Sell % of Top 5 Consumer Staples stocks

Source: Bloomberg, CMBIGM





Source: Bloomberg, CMBIGM



%

45 40

35

30

25

20

15

10

5


0

6/2022









Source: Bloomberg, CMBIGM






Source: Bloomberg, CMBIGM

Earnings & Valuations

Figure 39: Forward P/E of the US/Europe/Japan dropped to below 10-yr mean after recent weakness



Source: Bloomberg, CMBIGM

Figure 40: HSI' forward P/E approaching 10-yr mean, after earnings cuts and re-rating



Source: Bloomberg, CMBIGM



Figure 41: CSI 300's P/E returned to above 10-yr mean




Figure 43: EPS estimates of HSI were revised down by 1.0% last week



Figure 45: EPS estimates of A-shares were revised down by 0.8% last week



Figure 42: Many HSCI sectors' P/E are still near troughs




Source: Bloomberg, CMBIGM

Figure 44: EPS estimates of HSTECH Index were revised down by 2.6% last week



Figure 46: HK earnings revision: IT, Healthcare & **Consumer Discretionary down**




Source: Bloomberg, CMBIGM

Source: Bloomberg, CMBIGM



Figure 47: A-shares earnings revision: Financials & Staples up, IT & Healthcare down



Source: Bloomberg, CMBIGM



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report: (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report: (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not regulated or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in the second seco in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.